Curaleaf Launches Free CPD-Accredited Platform to Close Medical Cannabis Training Gap …
#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians lack standardized, accredited training in medical cannabis despite increasing patient requests for this treatment option, making accessible educational resources critical for informed prescribing decisions. This platform addresses a documented knowledge gap that has hindered clinicians’ ability to counsel patients on cannabis safety, efficacy, drug interactions, and appropriate clinical applications. Closing this training gap enables providers to make evidence-based recommendations rather than defaulting to blanket opposition or approval of cannabis use.
Curaleaf has launched a free continuing professional development (CPD) accredited educational platform designed to address the significant knowledge gap regarding medical cannabis in clinical practice. The platform covers foundational cannabis pharmacology, core clinical knowledge, and management of specialist conditions, with content developed from Curaleaf’s research databases and input from medical specialists. This initiative directly addresses a major barrier to cannabis medicine adoption in clinical practice: many physicians lack formal training in cannabinoid pharmacology, drug interactions, dosing strategies, and patient selection criteria. By providing accessible, accredited education, the platform aims to increase clinician confidence and competence in recommending medical cannabis appropriately for eligible patients. For clinicians, readily available CME-accredited resources can reduce practice uncertainty and support evidence-based prescribing decisions; for patients, clinician education translates to more informed recommendations and safer therapeutic use. Physicians seeking to incorporate cannabis medicine into their practice should evaluate whether this or similar credentialed training platforms can help fill their educational gaps before initiating prescribing.
“I appreciate industry efforts to improve clinician education on cannabis, but we need to be clear that training platforms funded by cannabis companies should be evaluated with the same critical eye we’d apply to any pharma-sponsored CME, and physicians using these resources ought to supplement them with independent, peer-reviewed literature to ensure they’re getting a complete clinical picture.”
💊 While industry-sponsored continuing professional development platforms can help address genuine knowledge gaps about cannabis pharmacology and clinical applications, healthcare providers should approach such resources with appropriate scrutiny regarding potential bias and commercial interests. Curaleaf’s educational offering may provide useful foundational content on cannabinoid mechanisms and evidence-based dosing, yet the framing of medical cannabis within a vendor’s platform warrants careful consideration of what evidence is highlighted, what remains contested, and whether recommendations align with independent clinical guidelines and regulatory standards in your jurisdiction. The medical cannabis landscape remains characterized by significant evidence gaps, variable efficacy across conditions, and evolving legal status that differs substantially by region, making it essential that practitioners supplement any single educational source with peer-reviewed literature and institutional policies. Rather than relying primarily on industry-sponsored training, clinicians should seek balanced, accredited education from independent sources while maintaining appropriate caution about prescribing patterns that may be inadvertently shaped by commercial interests.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
